- Merck: FDA approves Oxytrol for Women, creating overactive bladder category in OTC
- Report: Pfizer seeks aid of PBMs in efforts to block generic versions of Lipitor
- FDA gives Wockhardt tentative approval for bipolar, schizophrenia drug
- Drug Store Shopping Report Card
- Walgreens all systems go for 2013; reports 4Q, annual sales
NEW YORK — A cancer drug made by Genentech and Astellas is no longer available through ordinary retail channels and is now available only through a limited-distribution network.
Cancer-focused specialty pharmacy Onco360 said that effective Monday, the drug Tarceva (erlotinib) would no longer be available through retail pharmacies and that had joined a limited-distribution network that the drug makers had set up for the drug. Tarceva is used for treating advanced non-small cell lung cancer and pancreatic cancer.
"The Onco360 model of oncology-focused pharmacy care continues to resonate with oncologists and patients, and we are very pleased that manufacturers continue to acknowledge that by including Onco360 in their limited-distribution networks," Onco360 SVP trade channel strategy relations Ron Bookman said.